| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | F13B |
| Uniprot No | P05160 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-661aa |
| 氨基酸序列 | MRLKNLTFII ILIISGELYA EEKPCGFPHV ENGRIAQYYY TFKSFYFPMS IDKKLSFFCL AGYTTESGRQ EEQTTCTTEG WSPEPRCFKK CTKPDLSNGY ISDVKLLYKI QENMRYGCAS GYKTTGGKDE EVVQCLSDGW SSQPTCRKEH ETCLAPELYN GNYSTTQKTF KVKDKVQYEC ATGYYTAGGK KTEEVECLTY GWSLTPKCTK LKCSSLRLIE NGYFHPVKQT YEEGDVVQFF CHENYYLSGS DLIQCYNFGW YPESPVCEGR RNRCPPPPLP INSKIQTHST TYRHGEIVHI ECELNFEIHG SAEIRCEDGK WTEPPKCIEG QEKVACEEPP FIENGAANLH SKIYYNGDKV TYACKSGYLL HGSNEITCNR GKWTLPPECV ENNENCKHPP VVMNGAVADG ILASYATGSS VEYRCNEYYL LRGSKISRCE QGKWSSPPVC LEPCTVNVDY MNRNNIEMKW KYEGKVLHGD LIDFVCKQGY DLSPLTPLSE LSVQCNRGEV KYPLCTRKES KGMCTSPPLI KHGVIISSTV DTYENGSSVE YRCFDHHFLE GSREAYCLDG MWTTPPLCLE PCTLSFTEME KNNLLLKWDF DNRPHILHGE YIEFICRGDT YPAELYITGS ILRMQCDRGQ LKYPRCIPRQ STLSYQEPLR T |
| 预测分子量 | 75 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于F13B重组蛋白的模拟参考文献示例(注：内容为虚构，仅作格式参考)：
---
1. **文献名称**: *Functional Characterization of F13B Recombinant Protein in Viral Envelopment*
**作者**: Smith J, et al.
**摘要**: 研究通过大肠杆菌表达系统重组表达痘病毒F13B蛋白，并利用体外实验证实其参与病毒包膜形成，敲除F13B导致病毒粒子释放缺陷，表明其在病毒形态发生中的关键作用。
2. **文献名称**: *Crystal Structure Analysis of F13B Protein and Implications for Drug Design*
**作者**: Lee S, Kim M.
**摘要**: 解析了F13B重组蛋白的X射线晶体结构(分辨率2.8Å)，发现其具有独特的疏水结构域，可能作为抗病毒药物靶点，为基于结构的抑制剂设计提供依据。
3. **文献名称**: *F13B Recombinant Protein as a Novel Adjuvant for DNA Vaccines*
**作者**: Garcia R, et al.
**摘要**: 评估F13B重组蛋白作为疫苗佐剂的潜力，实验显示其可增强小鼠模型中对流感抗原的Th1免疫应答，提示其在免疫增强剂开发中的应用前景。
4. **文献名称**: *Role of F13B in Host-Pathogen Interaction: Insights from Recombinant Protein Studies*
**作者**: Wang X, et al.
**摘要**: 通过Pull-down实验发现F13B重组蛋白与宿主细胞膜蛋白ANNEXIN A2互作，可能介导病毒侵入，为阻断病毒感染的干预策略提供新方向。
---
如需真实文献，建议通过PubMed、Google Scholar等平台检索关键词(如"F13B recombinant protein"或结合具体研究领域)。
**Background of F13B Recombinant Protein**
The F13B recombinant protein, derived from the human coagulation factor XIII B subunit (FXIII-B), plays a critical role in blood coagulation and tissue repair. Factor XIII is a transglutaminase enzyme composed of two catalytic A subunits (FXIII-A) and two carrier/inhibitory B subunits (FXIII-B), forming a tetrameric complex (FXIII-A₂B₂) in plasma. FXIII-B regulates the stability, solubility, and activation of FXIII-A, which crosslinks fibrin polymers during clot formation, enhancing clot strength and resistance to fibrinolysis.
Recombinant F13B is engineered using biotechnological methods, typically expressed in mammalian cell systems (e.g., Chinese Hamster Ovary cells) to ensure proper post-translational modifications. Its production addresses challenges in studying and treating FXIII deficiencies, rare bleeding disorders linked to mutations in F13B or F13A genes. Clinically, recombinant FXIII concentrates (containing both subunits) are used as replacement therapy, but isolated F13B recombinant protein serves as a valuable tool for mechanistic studies, such as exploring subunit interactions, FXIII activation kinetics, and its non-hemostatic roles in angiogenesis, wound healing, and immune response.
Research on F13B also extends to conditions like thrombosis, fibrosis, and inflammatory diseases, where dysregulated FXIII activity is implicated. By providing a purified, consistent protein source, recombinant F13B facilitates drug development, diagnostic assay standardization, and structure-function analyses. Its application underscores the intersection of hematology, biotechnology, and molecular medicine in addressing both congenital and acquired coagulation disorders.
×
